Vera Therapeutics (VERA) Assets Average (2021 - 2026)

Vera Therapeutics has reported Assets Average for 6 years, with the latest figure at $678.2 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 7.16% year-over-year to $678.2 million; the trailing twelve-month figure through Mar 2026 stood at $678.2 million (up 7.16% YoY), and the FY2025 full-year result was $695.2 million, up 67.27% from the prior year.
• Assets Average for Q1 2026 stood at $678.2 million, up from $626.1 million in the prior quarter.
• The five-year high for Assets Average was $678.2 million in Q1 2026, with the low at $124.4 million in Q1 2022.
• Historically, Assets Average has averaged $351.0 million across 5 years, with a median of $297.5 million in 2024.
• Annual changes were most pronounced in 2024 — Assets Average surged 191.67% — and 2026, when it advanced 7.16%.
• Vera Therapeutics' Assets Average stood at $131.4 million in 2022, then surged by 33.62% to $175.6 million in 2023, then surged by 191.67% to $512.1 million in 2024, then rose by 22.26% to $626.1 million in 2025, then advanced by 8.32% to $678.2 million in 2026.
• The last three Assets Average figures came in at $678.2 million (Q1 2026), $626.1 million (Q4 2025), and $548.0 million (Q3 2025), per Business Quant data.